Cargando…

Real‐world outcomes of NSCLC patients receiving tissue or circulating tumor DNA‐guided osimertinib treatment

BACKGROUND: Osimertinib yields significant tumor responses and durations of progression‐free survival (PFS) in patients with acquired T790M mutations. However, the evidence supporting liquid biopsy‐guided treatment is still limited. This study examined the real‐world benefits of osimertinib in patie...

Descripción completa

Detalles Bibliográficos
Autores principales:	Su, Po‐Lan, Yang, Szu‐Chun, Chen, Yi‐Lin, Wu, Yi‐Lin, Lin, Chia‐Ying, Chang, Wei‐Yuan, Tseng, Yau‐Lin, Lai, Wu‐Wei, Ho, Chung‐Liang, Lin, Chien‐Chung, Su, Wu‐Chou
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6792511/ https://www.ncbi.nlm.nih.gov/pubmed/31433117 http://dx.doi.org/10.1002/cam4.2485

Ejemplares similares

The impact of EGFR mutations on the incidence and survival of stages I to III NSCLC patients with subsequent brain metastasis
por: Chang, Wei-Yuan, et al.
Publicado: (2018)

Brain MRI imaging characteristics predict treatment response and outcome in patients with de novo brain metastasis of EGFR-mutated NSCLC
por: Lin, Chia-Ying, et al.
Publicado: (2019)

Pembrolizumab and Chemotherapy Combination Prolonged Progression-Free Survival in Patients with NSCLC with High PD-L1 Expression and Low Neutrophil-to-Lymphocyte Ratio
por: Tsai, Jeng-Shiuan, et al.
Publicado: (2022)

Low neutrophil-to-lymphocyte ratio predicts overall survival benefit in advanced NSCLC patients with low PD-L1 expression and receiving chemoimmunotherapy
por: Chen, Chian-Wei, et al.
Publicado: (2023)

Preventing and treating brain metastases with three first-line EGFR-tyrosine kinase inhibitors in patients with EGFR mutation-positive advanced non-small cell lung cancer
por: Su, Po-Lan, et al.
Publicado: (2018)

The impact of driver mutation on the treatment outcome of early-stage lung cancer patients receiving neoadjuvant immunotherapy and chemotherapy
por: Su, Po-Lan, et al.
Publicado: (2022)

Extracellular Vesicle miR-200c Enhances Gefitinib Sensitivity in Heterogeneous EGFR-Mutant NSCLC
por: Lin, Chien-Chung, et al.
Publicado: (2021)

Improved survival in patients with unresectable stage III EGFR ‐mutant adenocarcinoma with upfront EGFR‐tyrosine kinase inhibitors
por: Wang, Sheng‐Yuan, et al.
Publicado: (2021)

First‐line treatment with irreversible tyrosine kinase inhibitors associated with longer OS in EGFR mutation‐positive non‐small cell lung cancer
por: Su, Po‐Lan, et al.
Publicado: (2020)

Effect of BIM expression on the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs
por: Chu, Chang-Yao, et al.
Publicado: (2023)

Age comorbidity scores as risk factors for 90‐day mortality in patients with a pancreatic head adenocarcinoma receiving a pancreaticoduodenectomy: A National Population‐Based Study
por: Shia, Ben‐Chang, et al.
Publicado: (2019)

Efficacy and safety of osimertinib in treating EGFR‐mutated advanced NSCLC: A meta‐analysis
por: Yi, Lilan, et al.
Publicado: (2019)

Economic Analysis of Tissue-First, Plasma-First, and Complementary NGS Approaches for Treatment-Naïve Metastatic Lung Adenocarcinoma
por: Yang, Szu-Chun, et al.
Publicado: (2022)

Comparing survival and treatment response of patients with acquired T790M mutation second‐line osimertinib versus sequential treatment of chemotherapy followed by osimertinib: A real‐world study
por: Wang, Chin‐Chou, et al.
Publicado: (2021)

Durable Response to Combined Dabrafenib and Trametinib in a Patient With BRAF K601E Mutation-Positive Lung Adenocarcinoma: A Case Report
por: Su, Po-Lan, et al.
Publicado: (2021)

Durable Response of Dabrafenib, Trametinib, and Capmatinib in an NSCLC Patient With Co-Existing BRAF-KIAA1549 Fusion and MET Amplification: A Case Report
por: Chou, Yun-Tse, et al.
Publicado: (2022)

The Emergent Landscape of Detecting EGFR Mutations Using Circulating Tumor DNA in Lung Cancer
por: Huang, Wei-Lun, et al.
Publicado: (2015)

Effectiveness and safety of osimertinib in patients with metastatic EGFR T790M-positive NSCLC: An observational real-world study
por: Cao, Yabing, et al.
Publicado: (2019)

Osimertinib in NSCLC: Real-World Data From New Zealand
por: So, Yeojeong Jane, et al.
Publicado: (2020)

Chemotherapy outcomes in EGFR‐TKI resistant patients with common and uncommon EGFR mutation: An exploratory retrospective cohort study
por: Lin, Chien‐Yu, et al.
Publicado: (2023)

Ultra-Short Circulating Tumor DNA (usctDNA) in Plasma and Saliva of Non-Small Cell Lung Cancer (NSCLC) Patients
por: Li, Feng, et al.
Publicado: (2020)

The surgical resection of the primary tumor increases survival in patients with EGFR-mutant advanced non-small cell lung cancer: a tertiary center cohort study
por: Chen, Ying-Yuan, et al.
Publicado: (2022)

Recurrent aphthous stomatitis may be a precursor or risk factor for specific cancers: A case‐control frequency‐matched study
por: Qin, Lei, et al.
Publicado: (2018)

Liquid biopsy genotyping in lung cancer: ready for clinical utility?
por: Huang, Wei-Lun, et al.
Publicado: (2017)

Predictive significance of circulating tumor DNA against patients with T790M-positive EGFR-mutant NSCLC receiving osimertinib
por: Yamaguchi, Ou, et al.
Publicado: (2023)

miR‐155‐regulated mTOR and Toll‐like receptor 5 in gastric diffuse large B‐cell lymphoma
por: Huang, Wei‐Ting, et al.
Publicado: (2021)

Association between Helicobacter pylori infection and mortality risk in prostate cancer patients receiving androgen deprivation therapy: A real‐world evidence study
por: Liu, Jui‐Ming, et al.
Publicado: (2021)

Efficacy of Osimertinib in NSCLC Harboring Uncommon EGFR L861Q and Concurrent Mutations: Case Report and Literature Review
por: Lin, Ruiting, et al.
Publicado: (2021)

Osimertinib Rechallenge With Bevacizumab vs. Chemotherapy Plus Bevacizumab in EGFR-Mutant NSCLC Patients With Osimertinib Resistance
por: Cui, Qingli, et al.
Publicado: (2022)

Radiation dose escalation can improve local disease control and survival among esophageal cancer patients with large primary tumor volume receiving definitive chemoradiotherapy
por: Lin, Forn-Chia, et al.
Publicado: (2020)

Baseline plasma KL-6 level predicts adverse outcomes in patients with idiopathic pulmonary fibrosis receiving nintedanib: a retrospective real-world cohort study
por: Huang, Tang-Hsiu, et al.
Publicado: (2021)

The potential therapeutic regimen for overcoming resistance to osimertinib due to rare mutations in NSCLC
por: Han, Rui, et al.
Publicado: (2023)

Correction to: Baseline plasma KL-6 level predicts adverse outcomes in patients with idiopathic pulmonary fibrosis receiving nintedanib: a retrospective real-world cohort study
por: Huang, Tang-Hsiu, et al.
Publicado: (2021)

HBP1 promoter methylation augments the oncogenic β-catenin to correlate with prognosis in NSCLC
por: Tseng, Ruo-Chia, et al.
Publicado: (2014)

Case report: Salvage capmatinib therapy in KIF5B-MET fusion-positive lung adenocarcinoma with resistance to telisotuzumab vedotin
por: Lin, Chien-Yu, et al.
Publicado: (2022)

Serial Plasma Cell-Free Circulating Tumor DNA Tests Identify Genomic Alterations for Early Prediction of Osimertinib Treatment Outcome in EGFR T790M–Positive NSCLC
por: Liao, Bin-Chi, et al.
Publicado: (2020)

Complete Resolution of Sellar Metastasis in a Patient With NSCLC Treated With Osimertinib
por: Fan, WuQiang, et al.
Publicado: (2019)

Survival prognostic factors for metachronous second primary head and neck squamous cell carcinoma
por: Chen, Jin‐Hua, et al.
Publicado: (2016)

A combination of anti‐PD‐L1 mAb plus Lm‐LLO‐E6 vaccine efficiently suppresses tumor growth and metastasis in HPV‐infected cancers
por: Lin, Po‐Lin, et al.
Publicado: (2017)

Clinicopathological impact of VEGFR2 and VEGF‐C in patients with EGFR ‐major mutant NSCLC receiving osimertinib
por: Kaira, Kyoichi, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_9nubnj2n1t4gm5tv9p2491roqs